In its ruling, the court denied Edwards Lifesciences‘ request for a permanent injunction to prohibit Medtronic from manufacturing its CoreValve System in the US.

As such, Medtronic does not anticipate any interruption to supply its CoreValve System.

The court also denied Edwards’ request for enhanced damages and also affirmed the jury’s verdict and damages award against Medtronic on patent infringement.

Medtronic disagreed with the conclusion and plans to appeal.

The court’s ruling has no impact on the Medtronic CoreValve US Pivotal Trial, which began in December.